MedPath

Asklepion Pharmaceuticals, LLC

Asklepion Pharmaceuticals, LLC logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

12

Active:5
Completed:4

Trial Phases

3 Phases

Phase 1:4
Phase 2:1
Phase 3:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (44.4%)
Phase 3
4 (44.4%)
Phase 2
1 (11.1%)

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Phase 3
Not yet recruiting
Conditions
Sickle Cell Disease
Interventions
Other: Placebo
First Posted Date
2025-05-25
Last Posted Date
2025-05-29
Lead Sponsor
Asklepion Pharmaceuticals, LLC
Target Recruit Count
120
Registration Number
NCT06989567
Locations
🇺🇸

Children's National Hospital, Washington, District of Columbia, United States

🇺🇸

University of Miami, Coral Gables, Florida, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

and more 3 locations

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Phase 3
Recruiting
Conditions
Ventricular Septal Defect
Atrioventricular Septal Defect
Primum Atrial Septal Defect
Interventions
First Posted Date
2022-02-23
Last Posted Date
2023-08-21
Lead Sponsor
Asklepion Pharmaceuticals, LLC
Target Recruit Count
97
Registration Number
NCT05253209
Locations
🇺🇸

Children's of Alabama, Birmingham, Alabama, United States

🇺🇸

Children's Hospital of Colorado, Aurora, Colorado, United States

🇺🇸

Heart Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 7 locations

L-citrulline Injection in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting With Vaso-Occlusive Crisis (VOC)

Phase 1
Recruiting
Conditions
Acute Vaso Occlusive Crisis (VOC)
Interventions
Other: D5 1/2NS
First Posted Date
2021-04-21
Last Posted Date
2023-08-21
Lead Sponsor
Asklepion Pharmaceuticals, LLC
Target Recruit Count
120
Registration Number
NCT04852172
Locations
🇺🇸

Children's National Hospital, Washington DC, District of Columbia, United States

🇺🇸

The University of Mississippi Medical Center, Jackson, Mississippi, United States

Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

Phase 2
Completed
Conditions
Acute Hypoxemic Respiratory Failure
Interventions
Drug: Placebo
First Posted Date
2020-09-30
Last Posted Date
2023-02-22
Lead Sponsor
Asklepion Pharmaceuticals, LLC
Target Recruit Count
65
Registration Number
NCT04570384
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects

Phase 3
Completed
Conditions
Acute Lung Injury
Interventions
Other: Placebo
First Posted Date
2016-09-08
Last Posted Date
2023-02-23
Lead Sponsor
Asklepion Pharmaceuticals, LLC
Target Recruit Count
189
Registration Number
NCT02891837
Locations
🇺🇸

University of Alabama, Birmingham, Alabama, United States

🇺🇸

Loma Linda University Children's Hospital, Loma Linda, California, United States

🇺🇸

University of California Davis Medical Center, Sacramento, California, United States

and more 26 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.